MOLOGEN AG attains the goals of the renal cancer study with MGN1601 ahead of schedule

MOLOGEN AG appoints Dr. Stefan M. Manth to the scientific advisory board

MOLOGEN AG quarterly report:

Both clinical studies progressing well

MOLOGEN AG First evaluation data on clinical trial with MGN1601 - results for renal cancer therapy considerably better than anticipated

MOLOGEN AG Interim Financial Report: Clinical cancer studies are progressing according to plan

MOLOGEN AG will next clinically investigate the efficacy of MGN1703 in lung cancer

MOLOGEN AG makes a successful start to the new financial year - quarterly report presented

MOLOGEN AG: Inclusion criteria for patients of the clinical trial with colorectal cancer medicine MGN1703 are expanded

MOLOGEN AG: Approval-relevant clinical trial with colorectal cancer medicine MGN1703 also started in Russia

MOLOGEN AG: well equipped for the current financial year

Capital increase at MOLOGEN AG completed very successfully

MOLOGEN AG announces the purchase price for new shares

MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703 in phase II/III study - data will be presented at the symposium of ASCO in San Francisco.

MOLOGEN AG: Clinical studies of the renal cancer medication MGN1601 stand out from the start with excellent data about safety and tolerance. - Further patient recruitment can be performed without additional observation time.

MOLOGEN AG is starting an important business year with a capital increase

MOLOGEN AG announces its decision on a capital increase from authorized capital